Metal-enhanced intrinsic fluorescence of nucleic acids using platinum nanostructured substrates.

N. Akbay,Farhad Mahdavi,J. Lakowicz,K. Ray

DOI: https://doi.org/10.1016/J.CPLETT.2012.08.020

IF: 2.719

2012-10-01

Chemical Physics Letters

Abstract:

What problem does this paper attempt to address?

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Vincent C Marconi,Athimalaipet V Ramanan,Stephanie de Bono,Cynthia E Kartman,Venkatesh Krishnan,Ran Liao,Maria Lucia B Piruzeli,Jason D Goldman,Jorge Alatorre-Alexander,Rita de Cassia Pellegrini,Vicente Estrada,Mousumi Som,Anabela Cardoso,Sujatro Chakladar,Brenda Crowe,Paulo Reis,Xin Zhang,David H Adams,E Wesley Ely,COV-BARRIER Study Group,Mi-Young Ahn,Miriam Akasbi,Javier David Altclas,Federico Ariel,Horacio Alberto Ariza,Chandrasekhar Atkar,Anselmo Bertetti,Meenakshi Bhattacharya,Maria Luisa Briones,Akshay Budhraja,Aaliya Burza,Adrian Camacho Ortiz,Roberto Caricchio,Marcelo Casas,Valeria Cevoli Recio,Won Suk Choi,Emilia Cohen,Angel Comulada-Rivera,Paul Cook,Dora Patricia Cornejo Juarez,Carnevali Daniel,Luiz Fernando Degrecci Relvas,Jose Guillermo Dominguez Cherit,Todd Ellerin,Dmitry Enikeev,Suzana Erico Tanni Minamoto,Elie Fiss,Motohiko Furuichi,Kleber Giovanni Luz,Omar Gonzalez,Ivan Gordeev,Thomas Gruenewald,Victor Augusto Hamamoto Sato,Eun Young Heo,Jung Yeon Heo,Maria Hermida,Yuji Hirai,David Hutchinson,Claudio Iastrebner,Octavian Ioachimescu,Manish Jain,Maria Patelli Juliani Souza Lima,Akram Khan,Andreas E Kremer,Thomas Lawrie,Mark MacElwee,Farah Madhani-Lovely,Vinay Malhotra,Michel Fernando Martínez Resendez,James McKinnell,Patrick Milligan,Cesar Minelli,Miguel Angel Moran Rodriguez,Maria Leonor Parody,Priscila Paulin,Priscilla Pemu,Ana Carolina Procopio Carvalho,Massimo Puoti,Joshua Purow,Mayur Ramesh,Alvaro Rea Neto,Philip Robinson,Cristhieni Rodrigues,Gustavo Rojas Velasco,Jose Francisco Kerr Saraiva,Morton Scheinberg,Stefan Schreiber,Dario Scublinsky,Anete Sevciovic Grumach,Imad Shawa,Jesus Simon Campos,Nidhi Sofat,Christoph D Spinner,Eduardo Sprinz,Roger Stienecker,Jose Suarez,Natsuo Tachikawa,Hasan Tahir,Brian Tiffany,Alexander Vishnevsky,Adilson Westheimer Cavalcante,Kapil Zirpe

DOI: https://doi.org/10.1016/S2213-2600(21)00331-3

Abstract:Background: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19. Methods: In this phase 3, double-blind, randomised, placebo-controlled trial, participants were enrolled from 101 centres across 12 countries in Asia, Europe, North America, and South America. Hospitalised adults with COVID-19 receiving standard of care were randomly assigned (1:1) to receive once-daily baricitinib (4 mg) or matched placebo for up to 14 days. Standard of care included systemic corticosteroids, such as dexamethasone, and antivirals, including remdesivir. The composite primary endpoint was the proportion who progressed to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28, assessed in the intention-to-treat population. All-cause mortality by day 28 was a key secondary endpoint, and all-cause mortality by day 60 was an exploratory endpoint; both were assessed in the intention-to-treat population. Safety analyses were done in the safety population defined as all randomly allocated participants who received at least one dose of study drug and who were not lost to follow-up before the first post-baseline visit. This study is registered with ClinicalTrials.gov, NCT04421027. Findings: Between June 11, 2020, and Jan 15, 2021, 1525 participants were randomly assigned to the baricitinib group (n=764) or the placebo group (n=761). 1204 (79·3%) of 1518 participants with available data were receiving systemic corticosteroids at baseline, of whom 1099 (91·3%) were on dexamethasone; 287 (18·9%) participants were receiving remdesivir. Overall, 27·8% of participants receiving baricitinib and 30·5% receiving placebo progressed to meet the primary endpoint (odds ratio 0·85 [95% CI 0·67 to 1·08], p=0·18), with an absolute risk difference of -2·7 percentage points (95% CI -7·3 to 1·9). The 28-day all-cause mortality was 8% (n=62) for baricitinib and 13% (n=100) for placebo (hazard ratio [HR] 0·57 [95% CI 0·41-0·78]; nominal p=0·0018), a 38·2% relative reduction in mortality; one additional death was prevented per 20 baricitinib-treated participants. The 60-day all-cause mortality was 10% (n=79) for baricitinib and 15% (n=116) for placebo (HR 0·62 [95% CI 0·47-0·83]; p=0·0050). The frequencies of serious adverse events (110 [15%] of 750 in the baricitinib group vs 135 [18%] of 752 in the placebo group), serious infections (64 [9%] vs 74 [10%]), and venous thromboembolic events (20 [3%] vs 19 [3%]) were similar between the two groups. Interpretation: Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard of care alone, and was associated with reduced mortality in hospitalised adults with COVID-19. Funding: Eli Lilly and Company. Translations: For the French, Japanese, Portuguese, Russian and Spanish translations of the abstract see Supplementary Materials section.
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

E Wesley Ely,Athimalaipet V Ramanan,Cynthia E Kartman,Stephanie de Bono,Ran Liao,Maria Lucia B Piruzeli,Jason D Goldman,José Francisco Kerr Saraiva,Sujatro Chakladar,Vincent C Marconi,COV-BARRIER Study Group,Jorge Alatorre-Alexander,Javier David Altclas,Marcelo Casas,Valeria CevoliRecio,Todd Ellerin,Kleber Giovanni Luz,Maria Patelli Juliani Souza Lima,Akram Khan,Priscila Paulin,Ana Carolina Procopio Carvalho,Gustavo Rojas Velasco,Jose Francisco Kerr Saraiva,Imad Shawa,Jesus Simon Campos,Brian Tiffany,Adilson Westheimer Cavalcante

DOI: https://doi.org/10.1016/S2213-2600(22)00006-6

Abstract:Background: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a multinational, phase 3, randomised, double-blind, placebo-controlled trial of baricitinib in patients with confirmed SARS-CoV-2 infection. We aimed to evaluate the efficacy and safety of baricitinib plus standard of care in critically ill hospitalised adults with COVID-19 requiring invasive mechanical ventilation or extracorporeal membrane oxygenation. Methods: This exploratory trial followed the study design of COV-BARRIER in a critically ill cohort not included in the main phase 3 trial. The study was conducted across 18 hospitals in Argentina, Brazil, Mexico, and the USA. Participants (aged ≥18 years) hospitalised with laboratory-confirmed SARS-CoV-2 infection on baseline invasive mechanical ventilation or extracorporeal membrane oxygenation were randomly assigned (1:1) to baricitinib (4 mg) or placebo once daily for up to 14 days in combination with standard of care. Participants, study staff, and investigators were masked to study group assignment. Prespecified endpoints included all-cause mortality through days 28 and 60, number of ventilator-free days, duration of hospitalisation, and time to recovery through day 28. The efficacy analysis was done in the intention-to-treat population and the safety analysis was done in the safety population. This trial is registered with ClinicalTrials.gov, NCT04421027. Findings: Between Dec 23, 2020, and April 10, 2021, 101 participants were enrolled into the exploratory trial and assigned to baricitinib (n=51) or placebo (n=50) plus standard of care. Standard of care included baseline systemic corticosteroid use in 87 (86%) participants. Treatment with baricitinib significantly reduced 28-day all-cause mortality compared with placebo (20 [39%] of 51 participants died in the baricitinib group vs 29 [58%] of 50 in the placebo group; hazard ratio [HR] 0·54 [95% CI 0·31-0·96]; p=0·030; 46% relative reduction; absolute risk reduction 19%). A significant reduction in 60-day mortality was also observed in the baricitinib group compared with the placebo group (23 [45%] events vs 31 [62%]; HR 0·56 [95% CI 0·33-0·97]; p=0·027; 44% relative reduction; absolute risk reduction 17%). In every six baricitinib-treated participants, one additional death was prevented compared with placebo at days 28 and 60. The number of ventilator-free days did not differ significantly between treatment groups (mean 8·1 days [SD 10·2] in the baricitinib group vs 5·5 days [8·4] in the placebo group; p=0·21). The mean duration of hospitalisation in baricitinib-treated participants was not significantly shorter than in placebo-treated participants (23·7 days [SD 7·1] vs 26·1 days [3·9]; p=0·050). The rates of infections, blood clots, and adverse cardiovascular events were similar between treatment groups. Interpretation: In critically ill hospitalised patients with COVID-19 who were receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, treatment with baricitinib compared with placebo (in combination with standard of care, including corticosteroids) reduced mortality, which is consistent with the mortality reduction observed in less severely ill patients in the hospitalised primary COV-BARRIER study population. However, this was an exploratory trial with a relatively small sample size; therefore, further phase 3 trials are needed to confirm these findings. Funding: Eli Lilly and Company.
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

,Peter W Horby,Jonathan R Emberson,Marion Mafham,Mark Campbell,Leon Peto,Guilherme Pessoa-Amorim,Enti Spata,Natalie Staplin,Catherine Lowe,David R Chadwick,Christopher Brightling,Richard Stewart,Paul Collini,Abdul Ashish,Christopher A Green,Benjamin Prudon,Tim Felton,Anthony Kerry,J Kenneth Baillie,Maya H Buch,Jeremy N Day,Saul N Faust,Thomas Jaki,Katie Jeffery,Edmund Juszczak,Marian Knight,Wei Shen Lim,Alan Montgomery,Andrew Mumford,Kathryn Rowan,Guy Thwaites,Richard Haynes,Martin J Landray

DOI: https://doi.org/10.1101/2022.03.02.22271623

2022-03-03

Abstract:SUMMARY Background We evaluated the use of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, for the treatment of patients admitted to hospital because of COVID-19. Methods This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised for COVID-19. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group). The primary outcome was 28-day mortality assessed in the intention-to-treat population. A meta-analysis was conducted that included the results from the RECOVERY trial and all previous randomised controlled trials of baricitinib or other JAK inhibitor in patients hospitalised with COVID-19. The RECOVERY trial is registered with ISRCTN (50189673) and clinicaltrials.gov ( NCT04381936 ). Findings Between 2 February 2021 and 29 December 2021, 8156 patients were randomly allocated to receive usual care plus baricitinib versus usual care alone. At randomisation, 95% of patients were receiving corticosteroids and 23% receiving tocilizumab (with planned use within the next 24 hours recorded for a further 9%). Overall, 513 (12%) of 4148 patients allocated to baricitinib versus 546 (14%) of 4008 patients allocated to usual care died within 28 days (age-adjusted rate ratio 0·87; 95% CI 0·77-0·98; p=0·026). This 13% proportional reduction in mortality was somewhat smaller than that seen in a meta-analysis of 8 previous trials of a JAK inhibitor (involving 3732 patients and 425 deaths) in which allocation to a JAK inhibitor was associated with a 43% proportional reduction in mortality (rate ratio 0.57; 95% CI 0.45-0.72). Including the results from RECOVERY into an updated meta-analysis of all 9 completed trials (involving 11,888 randomised patients and 1484 deaths) allocation to baricitinib or other JAK inhibitor was associated with a 20% proportional reduction in mortality (rate ratio 0.80; 95% CI 0.71-0.89; p<0.001). In RECOVERY, there was no significant excess in death or infection due to non-COVID-19 causes and no excess of thrombosis, or other safety outcomes. Interpretation In patients hospitalised for COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials. The total randomised evidence to date suggests that JAK inhibitors (chiefly baricitinib) reduce mortality in patients hospitalised for COVID-19 by about one-fifth. Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056).
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Cameron R Wolfe,Kay M Tomashek,Thomas F Patterson,Carlos A Gomez,Vincent C Marconi,Mamta K Jain,Otto O Yang,Catharine I Paules,Guillermo M Ruiz Palacios,Robert Grossberg,Michelle S Harkins,Richard A Mularski,Nathaniel Erdmann,Uriel Sandkovsky,Eyad Almasri,Justino Regalado Pineda,Alexandra W Dretler,Diego Lopez de Castilla,Angela R Branche,Pauline K Park,Aneesh K Mehta,William R Short,Susan L F McLellan,Susan Kline,Nicole M Iovine,Hana M El Sahly,Sarah B Doernberg,Myoung-don Oh,Nikhil Huprikar,Elizabeth Hohmann,Colleen F Kelley,Mark Holodniy,Eu Suk Kim,Daniel A Sweeney,Robert W Finberg,Kevin A Grimes,Ryan C Maves,Emily R Ko,John J Engemann,Barbara S Taylor,Philip O Ponce,LuAnn Larson,Dante Paolo Melendez,Allan M Seibert,Nadine G Rouphael,Joslyn Strebe,Jesse L Clark,Kathleen G Julian,Alfredo Ponce de Leon,Anabela Cardoso,Stephanie de Bono,Robert L Atmar,Anuradha Ganesan,Jennifer L Ferreira,Michelle Green,Mat Makowski,Tyler Bonnett,Tatiana Beresnev,Varduhi Ghazaryan,Walla Dempsey,Seema U Nayak,Lori E Dodd,John H Beigel,Andre C Kalil,Lana Wahid,Emmanuel B. Walter,Akhila G. Belur,Grace Dreyer,Jan E. Patterson,Jason E. Bowling,Danielle O. Dixon,Angela Hewlett,Robert Odrobina,Jakrapun Pupaibool,Satish Mocherla,Suzana Lazarte,Meilani Cayabyab,Rezhan H. Hussein,Reshma R. Golamari,Kaleigh L. Krill,Sandra Rajme,Paul F. Riska,Barry S. Zingman,Gregory Mertz,Nestor Sosa,Paul A. Goepfert,Mezgebe Berhe,Emma Dishner,Mohamed Fayed,Kinsley Hubel,José Arturo Martinez-Orozco,Nora Bautista Felix,Sammy T. Elmor,Amer Ryan Bechnak,Youssef Saklawi,Jason W. Van Winkle,Diego F. Zea,Maryrose Laguio-Vila,Edward E. Walsh,Ann R. Falsey,Karen Carvajal,Robert C. Hyzy,Sinan Hanna,Norman Olbrich,Jessica J. Traenkner,Colleen S. Kraft,Pablo Tebas,Jillian T Baron,Corri Levine,Joy Nock,Joanne Billings,Hyun Kim,Marie-Carmelle Elie-Turenne,Jennifer A. Whitaker,Anne F. Luetkemeyer,Jay Dwyer,Emma Bainbridge,Pyoeng Gyun Choe,Chang Kyung Kang,Nikolaus Jilg,Valeria D Cantos,Divya R. Bhamidipati,Srinivasa Nithin Gopalsamy,Aarthi Chary,Jongtak Jung,Kyoung-Ho Song,Hong Bin Kim,Constance A. Benson,Kimberly McConnell,Jennifer P. Wang,Mireya Wessolossky,Katherine Perez,Taryn A Eubank,Catherine Berjohn,Gregory C. Utz,Patrick E.H. Jackson,Taison D. Bell,Heather M. Haughey,Abeer Moanna,Sushma Cribbs,Telisha Harrison,Christopher J. Colombo,Christina Schofield,Rhonda E. Colombo,Victor F. Tapson,Jonathan Grein,Fayyaz Sutterwala,Dilek Ince,Patricia L. Winokur,Monica Fung,Hannah Jang,David Wyles,Maria G. Frank,Ellen Sarcone,Henry Neumann,Anand Viswanathan,Sarah Hochman,Mark Mulligan,Benjamin Eckhardt,Ellie Carmody,Neera Ahuja,Kari Nadeau,David Svec,Jeffrey C. Macaraeg,Lee Morrow,Dave Quimby,Mary Bessesen,Lindsay Nicholson,Jill Adams,Princy Kumar,Allison A. Lambert,Henry Arguinchona,Radica Z. Alicic,Sho Saito,Norio Ohmagari,Ayako Mikami,David Chien Lye,Tau Hong Lee,Po Ying Chia,Lanny Hsieh,Alpesh N. Amin,Miki Watanabe,Keith A. Candiotti,Jose G. Castro,Maria A. Antor,Tida Lee,Tahaniyat Lalani,Richard M. Novak,Andrea Wendrow,Scott A. Borgetti,Sarah L. George,Daniel F. Hoft,James D. Brien,Stuart H. Cohen,George R. Thompson,Melony Chakrabarty,Faheem Guirgis,Richard T. Davey,Jocelyn Voell,Jeffrey R. Strich,David A. Lindholm,Katrin Mende,Trevor R. Wellington,Rekha R. Rapaka,Jennifer S. Husson,Andrea R. Levine,Seow Yen Tan,Humaira Shafi,Jaime M F Chien,David C. Hostler,Jordanna M. Hostler,Brian T. Shahan,David H. Adams,Anu Osinusi,Huyen Cao,Timothy H. Burgess,Julia Rozman,Kevin K. Chung,Christina Nieuwoudt,Jill A. El-Khorazaty,Heather Hill,Stephanie Pettibone,Nikki Gettinger,Theresa Engel,Teri Lewis,Jing Wang,Gregory A. Deye,Effie Nomicos,Rhonda Pikaart-Tautges,Mohamed Elsafy,Robert Jurao,Hyung Koo,Michael Proschan,Tammy Yokum,Janice Arega,Ruth Florese

DOI: https://doi.org/10.1016/s2213-2600(22)00088-1

IF: 102.642

2022-09-01

The Lancet Respiratory Medicine

Abstract:BACKGROUND: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to mechanical ventilation or death in hospitalised patients with COVID-19.METHODS: In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites), Singapore (two sites), and Japan (one site). Hospitalised adults (≥18 years) with COVID-19 who required supplemental oxygen administered by low-flow (≤15 L/min), high-flow (>15 L/min), or non-invasive mechanical ventilation modalities who met the study eligibility criteria (male or non-pregnant female adults ≥18 years old with laboratory-confirmed SARS-CoV-2 infection) were enrolled in the study. Patients were randomly assigned (1:1) to receive either baricitinib, remdesivir, and placebo, or dexamethasone, remdesivir, and placebo using a permuted block design. Randomisation was stratified by study site and baseline ordinal score at enrolment. All patients received remdesivir (≤10 days) and either baricitinib (or matching oral placebo) for a maximum of 14 days or dexamethasone (or matching intravenous placebo) for a maximum of 10 days. The primary outcome was the difference in mechanical ventilation-free survival by day 29 between the two treatment groups in the modified intention-to-treat population. Safety analyses were done in the as-treated population, comprising all participants who received one dose of the study drug. The trial is registered with ClinicalTrials.gov, NCT04640168.FINDINGS: Between Dec 1, 2020, and April 13, 2021, 1047 patients were assessed for eligibility. 1010 patients were enrolled and randomly assigned, 516 (51%) to baricitinib plus remdesivir plus placebo and 494 (49%) to dexamethasone plus remdesivir plus placebo. The mean age of the patients was 58·3 years (SD 14·0) and 590 (58%) of 1010 patients were male. 588 (58%) of 1010 patients were White, 188 (19%) were Black, 70 (7%) were Asian, and 18 (2%) were American Indian or Alaska Native. 347 (34%) of 1010 patients were Hispanic or Latino. Mechanical ventilation-free survival by day 29 was similar between the study groups (Kaplan-Meier estimates of 87·0% [95% CI 83·7 to 89·6] in the baricitinib plus remdesivir plus placebo group and 87·6% [84·2 to 90·3] in the dexamethasone plus remdesivir plus placebo group; risk difference 0·6 [95% CI -3·6 to 4·8]; p=0·91). The odds ratio for improved status in the dexamethasone plus remdesivir plus placebo group compared with the baricitinib plus remdesivir plus placebo group was 1·01 (95% CI 0·80 to 1·27). At least one adverse event occurred in 149 (30%) of 503 patients in the baricitinib plus remdesivir plus placebo group and 179 (37%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 7·5% [1·6 to 13·3]; p=0·014). 21 (4%) of 503 patients in the baricitinib plus remdesivir plus placebo group had at least one treatment-related adverse event versus 49 (10%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 6·0% [2·8 to 9·3]; p=0·00041). Severe or life-threatening grade 3 or 4 adverse events occurred in 143 (28%) of 503 patients in the baricitinib plus remdesivir plus placebo group and 174 (36%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 7·7% [1·8 to 13·4]; p=0·012).INTERPRETATION: In hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in similar mechanical ventilation-free survival by day 29, but dexamethasone was associated with significantly more adverse events, treatment-related adverse events, and severe or life-threatening adverse events. A more individually tailored choice of immunomodulation now appears possible, where side-effect profile, ease of administration, cost, and patient comorbidities can all be considered.FUNDING: National Institute of Allergy and Infectious Diseases.

respiratory system,critical care medicine
Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid Collaborative

Asad E Patanwala,Xuya Xiao,Thomas E Hills,Alisa M Higgins,Colin J McArthur,G Caleb Alexander,Hemalkumar B Mehta,National Covid Cohort Collaborative (N3C) Consortium,Adam B Wilcox,Adam M Lee,Alexis Graves,Alfred Jerrod Anzalone,Amin Manna,Amit Saha,Amy Olex,Andrea Zhou,Andrew E Williams,Andrew Southerland,Andrew T Girvin,Anita Walden,Anjali A Sharathkumar,Benjamin Amor,Benjamin Bates,Brian Hendricks,Brijesh Patel,Carolyn Bramante,Cavin Ward-Caviness,Charisse Madlock-Brown,Christine Suver,Christopher Chute,Christopher Dillon,Chunlei Wu,Clare Schmitt,Cliff Takemoto,Dan Housman,Davera Gabriel,David A Eichmann,Diego Mazzotti,Don Brown,Eilis Boudreau,Elaine Hill,Elizabeth Zampino,Emily Carlson Marti,Emily R Pfaff,Evan French,Farrukh M Koraishy,Federico Mariona,Fred Prior,George Sokos,Greg Martin,Harold Lehmann,Heidi Spratt,Hongfang Liu,Hythem Sidky,J W Awori Hayanga,Jami Pincavitch,Jaylyn Clark,Jeremy Richard Harper,Jessica Islam,Jin Ge,Joel Gagnier,Joel H Saltz,Joel Saltz,Johanna Loomba,John Buse,Jomol Mathew,Joni L Rutter,Julie A McMurry,Justin Guinney,Justin Starren,Karen Crowley,Katie Rebecca Bradwell,Kellie M Walters,Ken Wilkins,Kenneth R Gersing,Kenrick Dwain Cato,Kimberly Murray,Kristin Kostka,Lavance Northington,Lee Allan Pyles,Leonie Misquitta,Lesley Cottrell,Lili Portilla,Mariam Deacy,Mark M Bissell,Marshall Clark,Mary Emmett,Mary Morrison Saltz,Matvey B Palchuk,Melissa A Haendel,Meredith Adams,Meredith Temple-O'Connor,Michael G Kurilla,Michele Morris,Nabeel Qureshi,Nasia Safdar,Nicole Garbarini,Noha Sharafeldin,Ofer Sadan,Patricia A Francis,Penny Wung Burgoon,Peter Robinson,Philip R O Payne,Rafael Fuentes,Randeep Jawa,Rebecca Erwin-Cohen,Rena Patel,Richard A Moffitt,Richard L Zhu,Rishi Kamaleswaran,Robert Hurley,Robert T Miller,Saiju Pyarajan,Sam G Michael,Samuel Bozzette,Sandeep Mallipattu,Satyanarayana Vedula,Scott Chapman,Shawn T O'Neil,Soko Setoguchi,Stephanie S Hong,Steve Johnson,Tellen D Bennett,Tiffany Callahan,Umit Topaloglu,Usman Sheikh,Valery Gordon,Vignesh Subbian,Warren A Kibbe,Wenndy Hernandez,Will Beasley,Will Cooper,William Hillegass,Xiaohan Tanner Zhang

DOI: https://doi.org/10.1097/CCM.0000000000006444

2024-10-04

Abstract:Objectives: COVID-19 treatment guidelines recommend baricitinib or tocilizumab for the management of hospitalized patients with COVID-19. We compared the effectiveness of baricitinib vs. tocilizumab on mortality and clinical outcomes among hospitalized patients with COVID-19. Design: Multicenter, retrospective, propensity-weighted cohort study using a target trial emulation approach. Setting: The National COVID Cohort Collaborative (N3C), which is the largest electronic health records data on COVID-19 in the United States. The setting included 75 hospitals. Patients: Adults who were hospitalized for COVID-19. Interventions: Newly initiated on baricitinib or tocilizumab. Measurements and main results: Our primary outcome was 28-day mortality. We used propensity scores with inverse probability of treatment weights (IPTWs) to control bias and confounding while comparing treatments. Among 10,661 individuals included in the study, 6,229 (58.4%) received baricitinib and 4,432 (41.6%) tocilizumab. Overall, the mean age of the cohort was 60.0 ± 15.1 years, 6429 (60.3%) were male, and 19.2% received invasive mechanical ventilation. After IPTW adjustment, baricitinib use was associated with lower 28-day mortality (odds ratio [OR], 0.91; 95% CI, 0.85-0.98) and hospital (OR, 0.88; 95% CI, 0.82-0.94) mortality compared with tocilizumab. Baricitinib was also associated with shorter hospital length of stay (incident rate ratio, 0.92; 95% CI, 0.90-0.94) and lower rates of hospital-acquired infections (OR, 0.86; 95% CI, 0.75-0.99), although no difference in ICU length of stay was noted between the two groups. Conclusions: In this large, diverse cohort of U.S. hospitalized adults with COVID-19, baricitinib was associated with significantly lower 28-day mortality, hospital mortality, shorter hospital length of stay, and less hospital-acquired infections compared with tocilizumab.
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Andre C. Kalil,Thomas F. Patterson,Aneesh K. Mehta,Kay M. Tomashek,Cameron R. Wolfe,Varduhi Ghazaryan,Vincent C. Marconi,Guillermo M. Ruiz-Palacios,Lanny Hsieh,Susan Kline,Victor Tapson,Nicole M. Iovine,Mamta K. Jain,Daniel A. Sweeney,Hana M. El Sahly,Angela R. Branche,Justino Regalado Pineda,David C. Lye,Uriel Sandkovsky,Anne F. Luetkemeyer,Stuart H. Cohen,Robert W. Finberg,Patrick E.H. Jackson,Babafemi Taiwo,Catherine I. Paules,Henry Arguinchona,Paul Goepfert,Neera Ahuja,Maria Frank,Myoung-don Oh,Eu S. Kim,Seow Y. Tan,Richard A. Mularski,Henrik Nielsen,Philip O. Ponce,Barbara S. Taylor,LuAnn Larson,Nadine G. Rouphael,Youssef Saklawi,Valeria D. Cantos,Emily R. Ko,John J. Engemann,Alpesh N. Amin,Miki Watanabe,Joanne Billings,Marie-Carmelle Elie,Richard T. Davey,Timothy H. Burgess,Jennifer Ferreira,Michelle Green,Mat Makowski,Anabela Cardoso,Stephanie de Bono,Tyler Bonnett,Michael Proschan,Gregory A. Deye,Walla Dempsey,Seema U. Nayak,Lori E. Dodd,John H. Beigel

DOI: https://doi.org/10.1056/NEJMoa2031994

2020-12-13

Abstract:In May 2020, the first stage of the Adaptive Covid-19 Treatment Trial (ACTT-1), a randomized, double-blind, placebo-controlled trial, showed that remdesivir is an effective treatment for hospitalized adult patients with coronavirus disease 2019 (Covid-19) pneumonia. 1 Despite the benefits of remdesivir, substantial morbidity and mortality due to Covid-19 remain. Emerging data suggest that disease severity may be due in part to a dysregulated inflammatory response. 2 It is postulated that mitigating the immune response and preventing a hyperinflammatory state may further improve clinical outcomes. Baricitinib, an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2, was predicted with the use of artificial intelligence algorithms to be a potential therapeutic against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 3,4 Baricitinib inhibits the intracellular signaling pathway of cytokines known to be elevated in severe Covid-19, including interleukin-2, interleukin-6, interleukin-10, interferon-γ, and granulocyte–macrophage colony-stimulating factor; acts against SARS-CoV-2 through the impairment of AP2-associated protein kinase 1 and the prevention of SARS-CoV-2 cellular entry and infectivity; and improves lymphocyte counts in patients with Covid-19. 3,5-8 In three case series of patients with Covid-19, baricitinib treatment was associated with both an improvement in oxygenation and a reduction in select inflammatory markers. 9-11 Randomized, controlled trials are needed to further understand the role of immunomodulation in patients with Covid-19. 12 After the successful completion of ACTT-1, we designed the next iteration of ACTT (ACTT-2) to evaluate whether the combination of baricitinib plus remdesivir was superior to remdesivir alone.
Giants in Chest Medicine: Claude Lenfant, MD.

E. Roccella

DOI: https://doi.org/10.1016/j.chest.2016.09.048

IF: 9.6

Chest

Abstract:
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial

Jozefien Declercq,Karel F A Van Damme,Elisabeth De Leeuw,Bastiaan Maes,Cedric Bosteels,Simon J Tavernier,Stefanie De Buyser,Roos Colman,Maya Hites,Gil Verschelden,Tom Fivez,Filip Moerman,Ingel K Demedts,Nicolas Dauby,Nicolas De Schryver,Elke Govaerts,Stefaan J Vandecasteele,Johan Van Laethem,Sebastien Anguille,Jeroen van der Hilst,Benoit Misset,Hans Slabbynck,Xavier Wittebole,Fabienne Liénart,Catherine Legrand,Marc Buyse,Dieter Stevens,Fre Bauters,Leen J M Seys,Helena Aegerter,Ursula Smole,Victor Bosteels,Levi Hoste,Leslie Naesens,Filomeen Haerynck,Linos Vandekerckhove,Pieter Depuydt,Eva van Braeckel,Sylvie Rottey,Isabelle Peene,Catherine Van Der Straeten,Frank Hulstaert,Bart N Lambrecht

DOI: https://doi.org/10.1016/S2213-2600(21)00377-5

Abstract:Background: Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interleukin (IL)-1 and IL-6 blockade have been proposed as therapeutic strategies in COVID-19, but study outcomes have been conflicting. We sought to study whether blockade of the IL-6 or IL-1 pathway shortened the time to clinical improvement in patients with COVID-19, hypoxic respiratory failure, and signs of systemic cytokine release syndrome. Methods: We did a prospective, multicentre, open-label, randomised, controlled trial, in hospitalised patients with COVID-19, hypoxia, and signs of a cytokine release syndrome across 16 hospitals in Belgium. Eligible patients had a proven diagnosis of COVID-19 with symptoms between 6 and 16 days, a ratio of the partial pressure of oxygen to the fraction of inspired oxygen (PaO2:FiO2) of less than 350 mm Hg on room air or less than 280 mm Hg on supplemental oxygen, and signs of a cytokine release syndrome in their serum (either a single ferritin measurement of more than 2000 μg/L and immediately requiring high flow oxygen or mechanical ventilation, or a ferritin concentration of more than 1000 μg/L, which had been increasing over the previous 24 h, or lymphopenia below 800/mL with two of the following criteria: an increasing ferritin concentration of more than 700 μg/L, an increasing lactate dehydrogenase concentration of more than 300 international units per L, an increasing C-reactive protein concentration of more than 70 mg/L, or an increasing D-dimers concentration of more than 1000 ng/mL). The COV-AID trial has a 2 × 2 factorial design to evaluate IL-1 blockade versus no IL-1 blockade and IL-6 blockade versus no IL-6 blockade. Patients were randomly assigned by means of permuted block randomisation with varying block size and stratification by centre. In a first randomisation, patients were assigned to receive subcutaneous anakinra once daily (100 mg) for 28 days or until discharge, or to receive no IL-1 blockade (1:2). In a second randomisation step, patients were allocated to receive a single dose of siltuximab (11 mg/kg) intravenously, or a single dose of tocilizumab (8 mg/kg) intravenously, or to receive no IL-6 blockade (1:1:1). The primary outcome was the time to clinical improvement, defined as time from randomisation to an increase of at least two points on a 6-category ordinal scale or to discharge from hospital alive. The primary and supportive efficacy endpoints were assessed in the intention-to-treat population. Safety was assessed in the safety population. This study is registered online with ClinicalTrials.gov (NCT04330638) and EudraCT (2020-001500-41) and is complete. Findings: Between April 4, and Dec 6, 2020, 342 patients were randomly assigned to IL-1 blockade (n=112) or no IL-1 blockade (n=230) and simultaneously randomly assigned to IL-6 blockade (n=227; 114 for tocilizumab and 113 for siltuximab) or no IL-6 blockade (n=115). Most patients were male (265 [77%] of 342), median age was 65 years (IQR 54-73), and median Systematic Organ Failure Assessment (SOFA) score at randomisation was 3 (2-4). All 342 patients were included in the primary intention-to-treat analysis. The estimated median time to clinical improvement was 12 days (95% CI 10-16) in the IL-1 blockade group versus 12 days (10-15) in the no IL-1 blockade group (hazard ratio [HR] 0·94 [95% CI 0·73-1·21]). For the IL-6 blockade group, the estimated median time to clinical improvement was 11 days (95% CI 10-16) versus 12 days (11-16) in the no IL-6 blockade group (HR 1·00 [0·78-1·29]). 55 patients died during the study, but no evidence for differences in mortality between treatment groups was found. The incidence of serious adverse events and serious infections was similar across study groups. Interpretation: Drugs targeting IL-1 or IL-6 did not shorten the time to clinical improvement in this sample of patients with COVID-19, hypoxic respiratory failure, low SOFA score, and low baseline mortality risk. Funding: Belgian Health Care Knowledge Center and VIB Grand Challenges program.
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Viviane C Veiga,João A G G Prats,Danielle L C Farias,Regis G Rosa,Leticia K Dourado,Fernando G Zampieri,Flávia R Machado,Renato D Lopes,Otavio Berwanger,Luciano C P Azevedo,Álvaro Avezum,Thiago C Lisboa,Salomón S O Rojas,Juliana C Coelho,Rodrigo T Leite,Júlio C Carvalho,Luis E C Andrade,Alex F Sandes,Maria C T Pintão,Claudio G Castro,Sueli V Santos,Thiago M L de Almeida,André N Costa,Otávio C E Gebara,Flávio G Rezende de Freitas,Eduardo S Pacheco,David J B Machado,Josiane Martin,Fábio G Conceição,Suellen R R Siqueira,Lucas P Damiani,Luciana M Ishihara,Daniel Schneider,Denise de Souza,Alexandre B Cavalcanti,Phillip Scheinberg

DOI: https://doi.org/10.1136/bmj.n84

2021-01-20

BMJ

Abstract:Abstract Objective To determine whether tocilizumab improves clinical outcomes for patients with severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial. Setting Nine hospitals in Brazil, 8 May to 17 July 2020. Participants Adults with confirmed covid-19 who were receiving supplemental oxygen or mechanical ventilation and had abnormal levels of at least two serum biomarkers (C reactive protein, D dimer, lactate dehydrogenase, or ferritin). The data monitoring committee recommended stopping the trial early, after 129 patients had been enrolled, because of an increased number of deaths at 15 days in the tocilizumab group. Interventions Tocilizumab (single intravenous infusion of 8 mg/kg) plus standard care (n=65) versus standard care alone (n=64). Main outcome measure The primary outcome, clinical status measured at 15 days using a seven level ordinal scale, was analysed as a composite of death or mechanical ventilation because the assumption of odds proportionality was not met. Results A total of 129 patients were enrolled (mean age 57 (SD 14) years; 68% men) and all completed follow-up. All patients in the tocilizumab group and two in the standard care group received tocilizumab. 18 of 65 (28%) patients in the tocilizumab group and 13 of 64 (20%) in the standard care group were receiving mechanical ventilation or died at day 15 (odds ratio 1.54, 95% confidence interval 0.66 to 3.66; P=0.32). Death at 15 days occurred in 11 (17%) patients in the tocilizumab group compared with 2 (3%) in the standard care group (odds ratio 6.42, 95% confidence interval 1.59 to 43.2). Adverse events were reported in 29 of 67 (43%) patients who received tocilizumab and 21 of 62 (34%) who did not receive tocilizumab. Conclusions In patients with severe or critical covid-19, tocilizumab plus standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality. Trial registration ClinicalTrials.gov NCT04403685 .
Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial

Djillali Annane,Sean J Pittock,Hrishikesh S Kulkarni,Brian W Pickering,Matt R Khoshnevis,Jason L Siegel,Charles A Powell,Pedro Castro,Tomoko Fujii,Derek Dunn,Keisha Smith,Sanjay Mitter,Shamsah Kazani,Austin Kulasekararaj

DOI: https://doi.org/10.1016/S2213-2600(23)00082-6

Abstract:Background: The complement pathway is a potential target for the treatment of severe COVID-19. We evaluated the safety and efficacy of ravulizumab, a terminal complement C5 inhibitor, in patients hospitalised with severe COVID-19 requiring invasive or non-invasive mechanical ventilation. Methods: This phase 3, multicentre, open-label, randomised controlled trial (ALXN1210-COV-305) enrolled adult patients (aged ≥18 years) from 31 hospitals in France, Japan, Spain, the UK, and the USA. Eligible patients had a confirmed diagnosis of SARS-CoV-2 that required hospitalisation and either invasive or non-invasive mechanical ventilation, with severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by CT scan or x-ray. We randomly assigned participants (2:1) to receive intravenous ravulizumab plus best supportive care (BSC) or BSC alone using a web-based interactive response system. Randomisation was in permuted blocks of six with stratification by intubation status. Bodyweight-based intravenous doses of ravulizumab were administered on days 1, 5, 10, and 15. The primary efficacy endpoint was survival based on all-cause mortality at day 29 in the intention-to-treat (ITT) population. Safety endpoints were analysed in all randomly assigned patients in the ravulizumab plus BSC group who received at least one dose of ravulizumab, and in all randomly assigned patients in the BSC group. The trial is registered with ClinicalTrials.gov, NCT04369469, and was terminated at interim analysis due to futility. Findings: Between May 10, 2020, and Jan 13, 2021, 202 patients were enrolled in the study and randomly assigned to ravulizumab plus BSC or BSC. 201 patients were included in the ITT population (135 in the ravulizumab plus BSC group and 66 in the BSC group). The ravulizumab plus BSC group comprised 96 (71%) men and 39 (29%) women with a mean age of 63·2 years (SD 13·23); the BSC group comprised 43 (65%) men and 23 (35%) women with a mean age of 63·5 years (12·40). Most patients (113 [84%] of 135 in the ravulizumab plus BSC group and 53 [80%] of 66 in the BSC group) were on invasive mechanical ventilation at baseline. Overall survival estimates based on multiple imputation were 58% for patients receiving ravulizumab plus BSC and 60% for patients receiving BSC (Mantel-Haenszel analysis: risk difference -0·0205; 95% CI -0·1703 to 0·1293; one-sided p=0·61). In the safety population, 113 (89%) of 127 patients in the ravulizumab plus BSC group and 56 (84%) of 67 in the BSC group had a treatment-emergent adverse event. Of these events, infections and infestations (73 [57%] vs 24 [36%] patients) and vascular disorders (39 [31%] vs 12 [18%]) were observed more frequently in the ravulizumab plus BSC group than in the BSC group. Five patients had serious adverse events considered to be related to ravulizumab. These events were bacteraemia, thrombocytopenia, oesophageal haemorrhage, cryptococcal pneumonia, and pyrexia (in one patient each). Interpretation: Addition of ravulizumab to BSC did not improve survival or other secondary outcomes. Safety findings were consistent with the known safety profile of ravulizumab in its approved indications. Despite the lack of efficacy, the study adds value for future research into complement therapeutics in critical illnesses by showing that C5 inhibition can be accomplished in severely ill patients. Funding: Alexion, AstraZeneca Rare Disease.
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial

G Moreno-González,A Mussetti,A Albasanz-Puig,I Salvador,A Sureda,C Gudiol,R Salazar,M Marin,M Garcia,V Navarro,I de la Haba Vaca,E Coma,G Sanz-Linares,X Dura,S Fontanals,G Serrano,C Cruz,R Mañez

DOI: https://doi.org/10.1186/s13063-021-05072-4

IF: 2.728

2021-02-05

Trials

Abstract:Objectives: Baricitinib is supposed to have a double effect on SARS-CoV2 infection. Firstly, it reduces the inflammatory response through the inhibition of the Januse-Kinase signalling transducer and activator of transcription (JAK-STAT) pathway. Moreover, it reduces the receptor mediated viral endocytosis by AP2-associated protein kinase 1 (AAK1) inhibition. We propose the use of baricinitib to prevent the progression of the respiratory insufficiency in SARS-CoV2 pneumonia in onco-haematological patients. In this phase Ib/II study, the primary objective in the safety cohort is to describe the incidence of severe adverse events associated with baricitinib administration. The primary objective of the randomized phase (baricitinib cohort versus standard of care cohort) is to evaluate the number of patients who did not require mechanical oxygen support since start of therapy until day +14 or discharge (whichever it comes first). The secondary objectives of the study (only randomized phase of the study) are represented by the comparison between the two arms of the study in terms of mortality and toxicity at day+30. Moreover, a description of the immunological related changes between the two arms of the study will be reported. Trial design: The trial is a phase I/II study with a safety run-in cohort (phase 1) followed by an open label phase II randomized controlled trial with an experimental arm compared to a standard of care arm. Participants: The study will be performed at the Institut Català d'Oncologia, a tertiary level oncological referral center in the Catalonia region (Spain). The eligibility criteria are: patients > 18 years affected by oncological diseases; ECOG performance status < 2 (Karnofsky score > 60%); a laboratory confirmed infection with SARS-CoV-2 by means of real -time PCR; radiological signs of low respiratory tract disease; absence of organ dysfunction (a total bilirubin within normal institutional limits, AST/ALT≤2.5 X institutional upper limit of normal, alkaline phosphatase ≤2.5 X institutional upper limit of normal, coagulation within normal institutional limits, creatinine clearance >30 mL/min/1.73 m2 for patients with creatinine levels above institutional normal); absence of HIV infection; no active or latent HBV or HCV infection. The exclusion criteria are: patients with oncological diseases who are not candidates to receive any active oncological treatment; hemodynamic instability at time of study enrollment; impossibility to receive oral medication; medical history of recent or active pulmonary embolism or deep venous thrombosis or patients at high-risk of suffering them (surgical intervention, immobilization); multi organ failure, rapid worsening of respiratory function with requirement of fraction of inspired oxygen (FiO2) > 50% or high-flow nasal cannula before initiation of study treatment; uncontrolled intercurrent illness (ongoing or severe active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements); allergy to one or more of study treatments; pregnant or breastfeeding women; positive pregnancy test in a pre-dose examination. Patients should have the ability to understand, and the willingness to sign, a written informed consent document; the willingness to accept randomization to any assigned treatment arm; and must agree not to enroll in another study of an investigational agent prior to completion of Day +28 of study. An electronic Case Report Form in the Research Electronic Data Capture (REDCap) platform will be used to collect the data of the trial. Removal from the study will apply in case of unacceptable adverse event(s), development of an intercurrent illness, condition or procedural complication, which could interfere with the patient's continued participation and voluntary patient withdrawal from study treatment (all patients are free to withdraw from participation in this study at any time, for any reasons, specified or unspecified, and without prejudice). Intervention and comparator: Treatment will be administered on an inpatient basis. We will compare the experimental treatment with baricitinib plus the institutional standard of care compared with the standard of care alone. During the phase I, we will define the dose-limiting toxicity of baricitinib and the dose to be used in the phase 2 part of the study. The starting baricitinib dose will be an oral tablet 4 mg-once daily which can be reduced to 2 mg depending on the observed toxicity. The minimum duration of therapy will be 5 days and it can be extended to 7 days. The standard of care will include the following therapies. Antibiotics will be individualized based on clinical suspicion, including the management of febrile neutropenia. Prophylaxis of thromboembolic disease will be administered to all participants. Remdesivir administration will be considered only in patients with severe pneumonia (SatO2 <94%) with less than 7 days of onset of symptoms and with supplemental oxygen requirements but not using high-flow nasal cannula, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). In the randomized phase, tocilizumab or interferon will not be allowed in the experimental arm. Tocilizumab can be used in patients in the standard of care arm at the discretion of the investigator. If it is prescribed it will be used according to the following criteria: patients who, according to his baseline clinical condition, would be an ICU tributary, interstitial pneumonia with severe respiratory failure, patients who are not on mechanical ventilation or ECMO and who are still progressing with corticoid treatment or if they are not candidates for corticosteroids. Mild ARDS (PAFI <300 mmHg) with radiological or blood gases deterioration that meets at least one of the following criteria: CRP >100mg/L D-Dimer >1,000μg/L LDH >400U/L Ferritin >700ng/ml Interleukin 6 ≥40ng/L. The use of tocilizumab is not recommended if there are AST/ALT values greater than 10 times the upper limit of normal, neutrophils <500 cells/mm3, sepsis due to other pathogens other than SARS-CoV-2, presence of comorbidity that can lead to a poor prognosis, complicated diverticulitis or intestinal perforation, ongoing skin infection. The dose will be that recommended by the Spanish Medicine Agency in patients ≥75Kg: 600mg dose whereas in patients <75kg: 400mg dose. Exceptionally, a second infusion can be assessed 12 hours after the first in those patients who experience a worsening of laboratory parameters after a first favourable response. The use of corticosteroids will be recommended in patients who have had symptoms for more than 7 days and who meet all the following criteria: need for oxygen support, non-invasive or invasive mechanical ventilation, acute respiratory failure or rapid deterioration of gas exchange, appearance or worsening of bilateral alveolar-interstitial infiltrates at the radiological level. In case of indication, it is recommended: dexamethasone 6mg/d p.o. or iv for 10 days or methylprednisolone 32mg/d orally or 30mg iv for 10 days or prednisone 40mg day p.o. for 10 days. Main outcomes: Phase 1 part: to describe the toxicity profile of baricitinib in COVID19 oncological patients during the 5-7 day treatment period and until day +14 or discharge (whichever it comes first). Phase 2 part: to describe the number of patients in the experimental arm that will not require mechanical oxygen support compared to the standard of care arm until day +14 or discharge (whichever it comes first). Randomisation: For the phase 2 of the study, the allocation ratio will be 1:1. Randomization process will be carried out electronically through the REDcap platform ( https://www.project-redcap.org/ ) BLINDING (MASKING): This is an open label study. No blinding will be performed. Numbers to be randomised (sample size): The first part of the study (safety run-in cohort) will consist in the enrollment of 6 to 12 patients. In this population, we will test the toxicity of the experimental treatment. An incidence of severe adverse events grade 3-4 (graded by Common Terminology Criteria for Adverse Events v.5.0) inferior than 33% will be considered sufficient to follow with the next part of the study. The second part of the study we will perform an interim analysis of efficacy at first 64 assessed patients and a definitive one will analyze 128 assessed patients. Interim and definitive tests will be performed considering in both cases an alpha error of 0.05. We consider for the control arm this rate is expected to be 0.60 and for the experimental arm of 0.80. Considering this data, a superiority test to prove a difference of 0.20 with an overall alpha error of 0.10 and a beta error of 0.2 will be performed. Considering a 5% of dropout rate, it is expected that a total of 136 patients, 68 for each study arm, will be required to complete study accrual. Trial status: Version 5.0. 14th October 2020 Recruitment started on the 16th of December 2020. Expected end of recruitment is June 2021. Trial registration: AEMPs: 20-0356 EudraCT: 2020-001789-12, https://www.clinicaltrialsregister.eu/ctr-search/search (Not publically available as Phase I trial) Clinical trials: BARCOVID19, https://www.clinicaltrials.gov/ (In progress) FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol."
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial

Andre C Kalil,Aneesh K Mehta,Thomas F Patterson,Nathaniel Erdmann,Carlos A Gomez,Mamta K Jain,Cameron R Wolfe,Guillermo M Ruiz-Palacios,Susan Kline,Justino Regalado Pineda,Anne F Luetkemeyer,Michelle S Harkins,Patrick E H Jackson,Nicole M Iovine,Victor F Tapson,Myoung-Don Oh,Jennifer A Whitaker,Richard A Mularski,Catharine I Paules,Dilek Ince,Jin Takasaki,Daniel A Sweeney,Uriel Sandkovsky,David L Wyles,Elizabeth Hohmann,Kevin A Grimes,Robert Grossberg,Maryrose Laguio-Vila,Allison A Lambert,Diego Lopez de Castilla,EuSuk Kim,LuAnn Larson,Claire R Wan,Jessica J Traenkner,Philip O Ponce,Jan E Patterson,Paul A Goepfert,Theresa A Sofarelli,Satish Mocherla,Emily R Ko,Alfredo Ponce de Leon,Sarah B Doernberg,Robert L Atmar,Ryan C Maves,Fernando Dangond,Jennifer Ferreira,Michelle Green,Mat Makowski,Tyler Bonnett,Tatiana Beresnev,Varduhi Ghazaryan,Walla Dempsey,Seema U Nayak,Lori Dodd,Kay M Tomashek,John H Beigel,ACTT-3 study group members,Angela Hewlett,Barbara S Taylor,Jason E Bowling,Ruth C Serrano,Nadine G Rouphael,Zanthia Wiley,Varun K Phadke,Laura Certain,Hannah N Imlay,John J Engemann,Emmanuel B Walter,Jessica Meisner,Sandra Rajme,Joanne Billings,Hyun Kim,Jose A Martinez-Orozco,Nora Bautista Felix,Sammy T Elmor,Laurel R Bristow,Gregory Mertz,Nestor Sosa,Taison D Bell,Miranda J West,Marie-Carmelle Elie-Turenne,Jonathan Grein,Fayyaz Sutterwala,Pyoeng Gyun Choe,Chang Kyung Kang,Hana M El Sahly,Kevin S Rhie,Rezhan H Hussein,Patricia L Winokur,Ayako Mikami,Sho Saito,Constance A Benson,Kimberly McConnell,Mezgebe Berhe,Emma Dishner,Maria G Frank,Ellen Sarcone,Pierre-Cedric B Crouch,Hannah Jang,Nikolaus Jilg,Katherine Perez,Charles Janak,Valeria D Cantos,Paulina A Rebolledo,John Gharbin,Barry S Zingman,Paul F Riska,Ann R Falsey,Edward E Walsh,Angela R Branche,Henry Arguinchona,Christa Arguinchona,Jason W Van Winkle,Diego F Zea,Jongtak Jung,Kyoung-Ho Song,Hong Bin Kim,Jay Dwyer,Emma Bainbridge,David C Hostler,Jordanna M Hostler,Brian T Shahan,Lanny Hsieh,Alpesh N Amin,Miki Watanabe,William R Short,Pablo Tebas,Jillian T Baron,Neera Ahuja,Evelyn Ling,Minjoung Go,Otto O Yang,Jenny Ahn,Rubi Arias,Rekha R Rapaka,Fleesie A Hubbard,James D Campbell,Stuart H Cohen,George R Thompson 3rd,Melony Chakrabarty,Stephanie N Taylor,Najy Masri,Alisha Lacour,Tida Lee,Tahaniyat Lalani,David A Lindholm,Ana Elizabeth Markelz,Katrin Mende,Christopher J Colombo,Christina Schofield,Rhonda E Colombo,Faheem Guirgis,Mark Holodniy,Aarthi Chary,Mary Bessesen,Noreen A Hynes,Lauren M Sauer,Vincent C Marconi,Abeer Moanna,Telisha Harrison,David C Lye,Sean W X Ong,Po Ying Chia,Nikhil Huprikar,Anuradha Ganesan,Christian Madar,Richard M Novak,Andrea Wendrow,Scott A Borgetti,Sarah L George,Daniel F Hoft,James D Brien,Susan L F McLellan,Corri Levine,Joy Nock,Seow Yen Tan,Humaira Shafi,Jaime M F Chien,Keith Candiotti,Robert W Finberg,Jennifer P Wang,Mireya Wessolossky,Gregory C Utz,Susan E Chambers,David S Stephens,Timothy H Burgess,Julia Rozman,Yann Hyvert,Andrea Seitzinger,Anu Osinusi,Huyen Cao,Kevin K Chung,Tom M Conrad,Kaitlyn Cross,Jill A El-Khorazaty,Heather Hill,Stephanie Pettibone,Michael R Wierzbicki,Nikki Gettinger,Theresa Engel,Teri Lewis,Jing Wang,Gregory A Deye,Effie Nomicos,Rhonda Pikaart-Tautges,Mohamed Elsafy,Robert Jurao,Hyung Koo,Michael Proschan,Richard Davey,Tammy Yokum,Janice Arega,Ruth Florese

DOI: https://doi.org/10.1016/S2213-2600(21)00384-2

Abstract:Background: Functional impairment of interferon, a natural antiviral component of the immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to compare the efficacy of interferon beta-1a in combination with remdesivir compared with remdesivir alone in hospitalised patients with COVID-19. Methods: We did a double-blind, randomised, placebo-controlled trial at 63 hospitals across five countries (Japan, Mexico, Singapore, South Korea, and the USA). Eligible patients were hospitalised adults (aged ≥18 years) with SARS-CoV-2 infection, as confirmed by a positive RT-PCR test, and who met one of the following criteria suggestive of lower respiratory tract infection: the presence of radiographic infiltrates on imaging, a peripheral oxygen saturation on room air of 94% or less, or requiring supplemental oxygen. Patients were excluded if they had either an alanine aminotransferase or an aspartate aminotransferase concentration more than five times the upper limit of normal; had impaired renal function; were allergic to the study product; were pregnant or breast feeding; were already on mechanical ventilation; or were anticipating discharge from the hospital or transfer to another hospital within 72 h of enrolment. Patients were randomly assigned (1:1) to receive intravenous remdesivir as a 200 mg loading dose on day 1 followed by a 100 mg maintenance dose administered daily for up to 9 days and up to four doses of either 44 μg interferon beta-1a (interferon beta-1a group plus remdesivir group) or placebo (placebo plus remdesivir group) administered subcutaneously every other day. Randomisation was stratified by study site and disease severity at enrolment. Patients, investigators, and site staff were masked to interferon beta-1a and placebo treatment; remdesivir treatment was given to all patients without masking. The primary outcome was time to recovery, defined as the first day that a patient attained a category 1, 2, or 3 score on the eight-category ordinal scale within 28 days, assessed in the modified intention-to-treat population, defined as all randomised patients who were classified according to actual clinical severity. Safety was assessed in the as-treated population, defined as all patients who received at least one dose of the assigned treatment. This trial is registered with ClinicalTrials.gov, NCT04492475. Findings: Between Aug 5, 2020, and Nov 11, 2020, 969 patients were enrolled and randomly assigned to the interferon beta-1a plus remdesivir group (n=487) or to the placebo plus remdesivir group (n=482). The mean duration of symptoms before enrolment was 8·7 days (SD 4·4) in the interferon beta-1a plus remdesivir group and 8·5 days (SD 4·3) days in the placebo plus remdesivir group. Patients in both groups had a time to recovery of 5 days (95% CI not estimable) (rate ratio of interferon beta-1a plus remdesivir group vs placebo plus remdesivir 0·99 [95% CI 0·87-1·13]; p=0·88). The Kaplan-Meier estimate of mortality at 28 days was 5% (95% CI 3-7%) in the interferon beta-1a plus remdesivir group and 3% (2-6%) in the placebo plus remdesivir group (hazard ratio 1·33 [95% CI 0·69-2·55]; p=0·39). Patients who did not require high-flow oxygen at baseline were more likely to have at least one related adverse event in the interferon beta-1a plus remdesivir group (33 [7%] of 442 patients) than in the placebo plus remdesivir group (15 [3%] of 435). In patients who required high-flow oxygen at baseline, 24 (69%) of 35 had an adverse event and 21 (60%) had a serious adverse event in the interferon beta-1a plus remdesivir group compared with 13 (39%) of 33 who had an adverse event and eight (24%) who had a serious adverse event in the placebo plus remdesivir group. Interpretation: Interferon beta-1a plus remdesivir was not superior to remdesivir alone in hospitalised patients with COVID-19 pneumonia. Patients who required high-flow oxygen at baseline had worse outcomes after treatment with interferon beta-1a compared with those given placebo. Funding: The National Institute of Allergy and Infectious Diseases (USA).
Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial

John Cafardi,Carole Miller,Howard Terebelo,Chad Tewell,Sadia Benzaquen,David Park,Pamela Egan,Daniel Lebovic,Kristen Pettit,Eric Whitman,Douglas Tremblay,Jonathan Feld,Sarah Buckley,Karisse Roman-Torres,Jennifer Smith,Adam Craig,John Mascarenhas

DOI: https://doi.org/10.1001/jamanetworkopen.2022.42918

2022-12-01

Abstract:Importance: The morbidity and mortality associated with COVID-19 remain high despite advances in standard of care therapy, and the role of anti-inflammatory agents that inhibit the interleukin 6/JAK2 pathway is still being elucidated. Objective: To evaluate the efficacy and safety of the oral JAK2/IRAK1 inhibitor pacritinib vs placebo in the treatment of adults with severe COVID-19. Design, setting, and participants: This phase 2, double-blind, placebo-controlled, randomized clinical trial enrolled hospitalized adult patients with severe COVID-19 at 21 centers across the US between June 2020 and February 2021, with approximately 1.5 months of safety follow-up per patient. Data analysis was performed from September 2021 to July 2022. Interventions: Patients were randomized 1:1 to standard of care plus pacritinib (400 mg per os on day 1 followed by 200 mg twice daily on days 2-14) vs placebo, for 14 days. Main outcomes and measures: The primary end point was death or need for invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) by day 28. All-cause mortality and safety were also assessed. Results: A total of 200 patients were randomized to pacritinib (99 patients; 56 men [56.6%]; median [range] age, 60 [19-87] years) or placebo (101 patients; 64 men [63.4%]; median [range] age 59 [28-94] years). The percentage requiring supplementary oxygen was 99.0% (98 patients) in the pacritinib group vs 98.0% (99 patients) in the placebo group. The percentage who progressed to IMV, ECMO, or death was 17.2% (17 patients) in the pacritinib group vs 22.8% (23 patients) in the placebo group (odds ratio, 0.62; 95% CI, 0.28-1.35; P = .23). Among patients with elevated interleukin 6, the rate was 17.5% (11 of 63 patients) in the pacritinib group vs 30.4% (21 of 96 patients) in the placebo group. The adverse event rate was similar for pacritinib vs placebo (78.1% [75 patients] vs 80.2% [81 patients]), with no excess in infection (14.6% [14 patients] vs 19.8% [20 patients]), bleeding (8.3% [8 patients] vs 10.9% [11 patients]), or thrombosis (8.3% [8 patients] vs 7.9% [8 patients]). Rates of grade 3 or higher adverse events were lower with pacritinib than placebo (29.2% [28 patients] vs 40.6% [41 patients]). Conclusions and relevance: The study did not meet its primary end point in patients with severe COVID-19. Subgroup analyses may indicate specific populations with hyperinflammation that could benefit from pacritinib, although further clinical trials would be needed to confirm these effects. Trial registration: ClinicalTrials.gov Identifier: NCT04404361.
Efficacy and Safety of Tocilizumab and Baricitinib among Patients Hospitalized for COVID-19: a Systematic Review and Meta-Analysis

Jin Zhang,Xiongxiong Fan,Xiaoyu Zhang,Fengli Jiang,Yiping Wu,Beibei Yang,Xinghuan Li,Dong Liu

DOI: https://doi.org/10.3389/fphar.2023.1293331

IF: 5.6

2023-01-01

Frontiers in Pharmacology

Abstract:Introduction: Tocilizumab and baricitinib are recommended treatment options for COVID-19 patients with hyperinflammatory response; however, there is a lack of systematic review directly evaluating their efficacy and safety. Objective: This review was conducted to evaluate the efficacy and safety of tocilizumab and baricitinib in the treatment of hospitalized patients with COVID-19. Methods: Relevant databases were searched for studies that compared the effect or safety of baricitinib or tocilizumab in hospitalized patients with COVID-19. The mortality was the main outcome. The hospital length of stay or adverse drug reactions were taken into consideration as secondary endpoints. The analyses were performed in Revman 5.3 or Stata 16.0. The protocol and analysis plan were pre-registered in PROSPERO, with the registration number CRD42023408219. Results: In total, 10 studies with 2,517 patients were included. The overall pooled data demonstrated that, there was no statistically significant difference in the 28-day mortality rate and the hospital length of stay between the tocilizumab and baricitinib (OR = 1.10, 95% CI = 0.80–1.51, p = 0.57; OR = −0.68, 95% CI = −2.24–0.87, p = 0.39). The adverse reactions including secondary infection rate, thrombotic and bleeding events, and acute liver injury of tocilizumab were significantly higher than that of baricitinib. (OR = 1.49, 95% CI = 1.18–1.88, p < 0.001,OR = 1.52, 95% CI = 1.11–2.08, p = 0.009; OR = 1.52, 95% CI = 1.11–2.08, p = 0.009; OR = 2.24, 95% CI = 1.49–3.35, p < 0.001). Conclusion: In patients hospitalized with COVID-19, no discernible difference in therapeutic efficacy was observed between tocilizumab and baricitinib; however, the group treated with baricitinib demonstrated a significantly lower incidence of adverse effects.
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease

Oghenekome Gbinigie,Emma Ogburn,Julie Allen,Jienchi Dorward,Melissa Dobson,Tracie-Ann Madden,Ly-Mee Yu,David M Lowe,Najib Rahman,Stavros Petrou,Duncan Richards,Kerenza Hood,Mahendra Patel,Benjamin R Saville,Joe Marion,Jane Holmes,May Ee Png,Gail Hayward,Mark Lown,Victoria Harris,Bhautesh Jani,Nigel Hart,Saye Khoo,Heather Rutter,Jem Chalk,Joseph F Standing,Judith Breuer,Layla Lavallee,Elizabeth Hadley,Lucy Cureton,Magdalena Benysek,Monique I Andersson,Nick Francis,Nicholas P B Thomas,Philip Evans,Oliver van Hecke,Mona Koshkouei,Maria Coates,Sarah Barrett,Clare Bateman,Jennifer Davies,Ivy Raymundo-Wood,Andrew Ustianowski,Jonathan Nguyen-Van-Tam,Andrew Carson-Stevens,Richard Hobbs,Paul Little,Christopher C Butler

DOI: https://doi.org/10.1136/bmjopen-2022-069176

IF: 3.006

2023-08-07

BMJ Open

Abstract:Introduction: There is an urgent need to determine the safety, effectiveness and cost-effectiveness of novel antiviral treatments for COVID-19 in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. Methods and analysis: PANORAMIC is a UK-wide, open-label, prospective, adaptive, multiarm platform, randomised clinical trial that evaluates antiviral treatments for COVID-19 in the community. A master protocol governs the addition of new antiviral treatments as they become available, and the introduction and cessation of existing interventions via interim analyses. The first two interventions to be evaluated are molnupiravir (Lagevrio) and nirmatrelvir/ritonavir (Paxlovid). Eligibility criteria: community-dwelling within 5 days of onset of symptomatic COVID-19 (confirmed by PCR or lateral flow test), and either (1) aged 50 years and over, or (2) aged 18-49 years with qualifying comorbidities. Registration occurs via the trial website and by telephone. Recruitment occurs remotely through the central trial team, or in person through clinical sites. Participants are randomised to receive either usual care or a trial drug plus usual care. Outcomes are collected via a participant-completed daily electronic symptom diary for 28 days post randomisation. Participants and/or their Trial Partner are contacted by the research team after days 7, 14 and 28 if the diary is not completed, or if the participant is unable to access the diary. The primary efficacy endpoint is all-cause, non-elective hospitalisation and/or death within 28 days of randomisation. Multiple prespecified interim analyses allow interventions to be stopped for futility or superiority based on prespecified decision criteria. A prospective economic evaluation is embedded within the trial. Ethics and dissemination: Ethical approval granted by South Central-Berkshire REC number: 21/SC/0393; IRAS project ID: 1004274. Results will be presented to policymakers and at conferences, and published in peer-reviewed journals. Trial registration number: ISRCTN30448031; EudraCT number: 2021-005748-31.
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)

Jatin Patel,Damon Bass,Albertus Beishuizen,Xavier Bocca Ruiz,Hatem Boughanmi,Anthony Cahn,Hugo Colombo,Gerard J. Criner,Katherine Davy,Javier de-Miguel-Díez,Pablo A. Doreski,Sofia Fernandes,Bruno François,Anubha Gupta,Kate Hanrott,Timothy Hatlen,Dave Inman,John D. Isaacs,Emily Jarvis,Natalia Kostina,Tatiana Kropotina,Jean-Claude Lacherade,Divya Lakshminarayanan,Pedro Martinez-Ayala,Charlene McEvoy,Ferhat Meziani,Mehran Monchi,Sumanta Mukherjee,Rosana Muñoz-Bermúdez,Jessica Neisen,Ciara O'Shea,Gaëtan Plantefeve,Lorrie Schifano,Lee E. Schwab,Zainab Shahid,Michinori Shirano,Julia E. Smith,Eduardo Sprinz,Charlotte Summers,Nicolas Terzi,Mark A. Tidswell,Yuliya Trefilova,Russell Williamson,Duncan Wyncoll,Mark Layton

DOI: https://doi.org/10.1183/13993003.01870-2021

2023-02-02

ERS Monograph

Abstract:Background Granulocyte–macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology and severity of COVID-19. Methods In this randomised, sequential, multicentre, placebo-controlled, double-blind study, adults aged 18–79 years (Part 1) or ≥70 years (Part 2) with severe COVID-19, respiratory failure and systemic inflammation (elevated C-reactive protein/ferritin) received a single intravenous infusion of otilimab 90 mg (human anti-GM-CSF monoclonal antibody) plus standard care (NCT04376684). The primary outcome was the proportion of patients alive and free of respiratory failure at Day 28. Results In Part 1 (n=806 randomised 1:1 otilimab:placebo), 71% of otilimab-treated patients were alive and free of respiratory failure at Day 28 versus 67% who received placebo; the model-adjusted difference of 5.3% was not statistically significant (95% CI –0.8–11.4%, p=0.09). A nominally significant model-adjusted difference of 19.1% (95% CI 5.2–33.1%, p=0.009) was observed in the predefined 70–79 years subgroup, but this was not confirmed in Part 2 (n=350 randomised) where the model-adjusted difference was 0.9% (95% CI –9.3–11.2%, p=0.86). Compared with placebo, otilimab resulted in lower serum concentrations of key inflammatory markers, including the putative pharmacodynamic biomarker CC chemokine ligand 17, indicative of GM-CSF pathway blockade. Adverse events were comparable between groups and consistent with severe COVID-19. Conclusions There was no significant difference in the proportion of patients alive and free of respiratory failure at Day 28. However, despite the lack of clinical benefit, a reduction in inflammatory markers was observed with otilimab, in addition to an acceptable safety profile.
The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis

Xueyang Zhang,Lianhan Shang,Guohui Fan,Xiaoying Gu,Jiuyang Xu,Yeming Wang,Lixue Huang,Bin Cao

DOI: https://doi.org/10.3389/fmed.2021.800492

IF: 3.9

2022-01-27

Frontiers in Medicine

Abstract:Background Cytokine storm observed in patients with severe Coronavirus Disease 2019 (COVID-19) contributes to poor clinical outcomes and increased mortality. Janus kinases (JAKs) are important mediators in the cytokine storm. Therefore, we conduct a living systematic review and meta-analysis of the literature investigating efficacy and safety of JAK inhibitors for patients with COVID-19. Methods Databases were searched up to December 1, 2021 for interventional and observational studies comparing JAK inhibitor treatment with concurrent control in patients with COVID-19. Efficacy and safety outcomes were evaluated by pooled risk ratio (RR). Results Of 3,170 records retrieved, 15 studies were eligible and 13 were evaluated in the meta-analysis ( n = 3,977). Based on data from three randomized controlled trials (RCTs), baricitinib treatment significantly decreased mortality by day 28 in hospitalized patients with COVID-19 (RR = 0.64, 95% CI 0.51–0.80) without increasing the incidence of adverse outcomes. In subgroup analysis, patients who required supplemental oxygen (RR = 0.62, 95% CI 0.41–0.95) or high-flow oxygen/non-invasive ventilation (RR = 0.59, 95% CI 0.42–0.85) at baseline benefited most. Pooled analysis of all eligible studies for JAK inhibitors (baricitinib, ruxolitinib, tofacitinib, and nezulcitinib) demonstrated a significant decrease in mortality (RR = 0.62, 95% CI 0.49–0.78) with no increase in the risk of adverse events. Conclusion Baricitinib probably decreases mortality in hospitalized adult patients with COVID-19, especially for patients who required supplemental oxygen or high-flow oxygen/non-invasive ventilation at baseline. The efficacy and safety of other JAK inhibitors, such as ruxolitinib, tofacitinib, and nezulcitinib, await more evidence. Systematic Review Registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021261414 , identifier: CRD42021261414.

medicine, general & internal
Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials

Wesley H Self,Matthew S Shotwell,Kevin W Gibbs,Marjolein de Wit,D Clark Files,Michelle Harkins,Kristin M Hudock,Lisa H Merck,Ari Moskowitz,Krystle D Apodaca,Aaron Barksdale,Basmah Safdar,Ali Javaheri,Jeffrey M Sturek,Harry Schrager,Nicole Iovine,Brian Tiffany,Ivor S Douglas,Joseph Levitt,Laurence W Busse,Adit A Ginde,Samuel M Brown,David N Hager,Katherine Boyle,Abhijit Duggal,Akram Khan,Michael Lanspa,Peter Chen,Michael Puskarich,Derek Vonderhaar,Lokesh Venkateshaiah,Nina Gentile,Yves Rosenberg,James Troendle,Amanda J Bistran-Hall,Josh DeClercq,Robert Lavieri,Meghan Morrison Joly,Michael Orr,Jill Pulley,Todd W Rice,Jonathan S Schildcrout,Matthew W Semler,Li Wang,Gordon R Bernard,Sean P Collins,ACTIV-4 Host Tissue Investigators,Richard C Becker,Gregory Del Zoppo,Peter Henke,Richard Holubkov,Maryl Johnson,Kim Kerr,Hannah I Lipman,Fedor Lurie,Bertram Pitt,Sara K Vesely,Jerome L Fleg,Dave Aamodt,J'Mario Ayers,Debra Clark,Jessica Collins,Maya Cook,Sheri Dixon,John Graves,Courtney Jordan,Christopher J Lindsell,Itzel Lopez,David McKeel,Dirk Orozco,Nelson Prato,Ally Qi,Madiha Qutab,Christa Stoughton,Krista Vermillion,Kelly Walsh,Stephanie Winchell,Taylor Young,Richard Franklin,Elizabeth Wagner,Thomas Walther,Mark Demitrack,Jakea Johnson,Ryan Walsh,Brian Bales,Karen Miller,Donna Torr,Harsh Barot,Leigha Landreth,Mary LaRose,Lisa Parks,J Pedro Teixeira,Sandra Cardenas,Juan A Ceniceros,Amy G Cunningham,Susan Kunkel,Debbie M Lovato,Brooklin Zimmerman,Thanh Nguyen,Wesley Zeger,Heather Nichols,Noah Wiedel,Stephanie Stilinovic,Carolyn Brokowski,Jing Lu,Muriel Solberg,Dana Lee,Kristopher Roach,Charlotte Tanner,Annette Taylor,Jennine Zumbahl,Aamer Syed,Jessica Mason,Patrick E H Jackson,Rachael W Coleman,Heather M Haughey,Kartik Cherabuddi,Nastasia James,Rebecca Wakeman,Christopher Duncan,Cynthia Montero,Angela J Rogers,Jennifer G Wilson,Rosemary Vojnik,Cynthia Perez,David Wyles,Terra D Hiller,Judy L Oakes,Ana Z Garcia,Michelle Gong,Amira Mohamed,Luke Andrea,Rahul Nair,William Nkemdirim,Brenda Lopez,Sabah Boujid,Martha Torres,Ofelia Garcia,Flora Martinez,Amiran Baduashvili,Jill Bastman,Lakshmi Chauhan,David J Douin,Lani Finck,Ashley Licursi,Caitlin Ten Lohuis,Sophia Zhang,William Bender,Santiago Tovar,Sharon Hayes,Nicholas Kurtzman,Elinita Rosseto,Douglas Scaffidi,Nathan Shapiro,Jonathan Pak,Gopal Allada,Genesis Briceno,Jose Peña,Minn Oh,Harith Ali,Sasha Beselman,Yolanda Eby,Vitaliy Klimov,R Duncan Hite,Hammad Tanzeem,Chris Droege,Jessica Winter,Susan Jackman,Antonina Caudill,Emad Bayoumi,Ethan Pascual,Po-En Chen,Simon Mucha,Nirosshan Thiruchelvam,Matthew Siuba,Omar Mehkri,Brian E Driver,Audrey F Hendrickson,Olivia R Kaus,Christina Ontiveros,Amy Riehm,Sylvia Laudun,Debra Hudock,Christopher Ensley,Valerie Shaner,Derek Isenberg,Hannah Reimer,Paul Cincola,Estelle S Harris,Sean J Callahan,Misty B Yamane,Macy Ag Barrios,Neeraj Desai,Amit Bharara,Michael Keller,Prat Majumder,Carrie Dohe,Jeanine D'Armiento,Monica Goldklang,Gebhard Wagener,Laura Fonseca,Itzel Valezquez-Sanchez,Nicholas J Johnson,Emily Petersen,Megan Fuentes,Maranda Newton,Stephanie Gundel,Vasisht Srinivasan,Tessa Steel,Bryce Robinson

DOI: https://doi.org/10.1001/jama.2023.3546

IF: 11.816

2023-04-11

JAMA

Abstract:Importance: Preclinical models suggest dysregulation of the renin-angiotensin system (RAS) caused by SARS-CoV-2 infection may increase the relative activity of angiotensin II compared with angiotensin (1-7) and may be an important contributor to COVID-19 pathophysiology. Objective: To evaluate the efficacy and safety of RAS modulation using 2 investigational RAS agents, TXA-127 (synthetic angiotensin [1-7]) and TRV-027 (an angiotensin II type 1 receptor-biased ligand), that are hypothesized to potentiate the action of angiotensin (1-7) and mitigate the action of the angiotensin II. Design, setting, and participants: Two randomized clinical trials including adults hospitalized with acute COVID-19 and new-onset hypoxemia were conducted at 35 sites in the US between July 22, 2021, and April 20, 2022; last follow-up visit: July 26, 2022. Interventions: A 0.5-mg/kg intravenous infusion of TXA-127 once daily for 5 days or placebo. A 12-mg/h continuous intravenous infusion of TRV-027 for 5 days or placebo. Main outcomes and measures: The primary outcome was oxygen-free days, an ordinal outcome that classifies a patient's status at day 28 based on mortality and duration of supplemental oxygen use; an adjusted odds ratio (OR) greater than 1.0 indicated superiority of the RAS agent vs placebo. A key secondary outcome was 28-day all-cause mortality. Safety outcomes included allergic reaction, new kidney replacement therapy, and hypotension. Results: Both trials met prespecified early stopping criteria for a low probability of efficacy. Of 343 patients in the TXA-127 trial (226 [65.9%] aged 31-64 years, 200 [58.3%] men, 225 [65.6%] White, and 274 [79.9%] not Hispanic), 170 received TXA-127 and 173 received placebo. Of 290 patients in the TRV-027 trial (199 [68.6%] aged 31-64 years, 168 [57.9%] men, 195 [67.2%] White, and 225 [77.6%] not Hispanic), 145 received TRV-027 and 145 received placebo. Compared with placebo, both TXA-127 (unadjusted mean difference, -2.3 [95% CrI, -4.8 to 0.2]; adjusted OR, 0.88 [95% CrI, 0.59 to 1.30]) and TRV-027 (unadjusted mean difference, -2.4 [95% CrI, -5.1 to 0.3]; adjusted OR, 0.74 [95% CrI, 0.48 to 1.13]) resulted in no difference in oxygen-free days. In the TXA-127 trial, 28-day all-cause mortality occurred in 22 of 163 patients (13.5%) in the TXA-127 group vs 22 of 166 patients (13.3%) in the placebo group (adjusted OR, 0.83 [95% CrI, 0.41 to 1.66]). In the TRV-027 trial, 28-day all-cause mortality occurred in 29 of 141 patients (20.6%) in the TRV-027 group vs 18 of 140 patients (12.9%) in the placebo group (adjusted OR, 1.52 [95% CrI, 0.75 to 3.08]). The frequency of the safety outcomes was similar with either TXA-127 or TRV-027 vs placebo. Conclusions and relevance: In adults with severe COVID-19, RAS modulation (TXA-127 or TRV-027) did not improve oxygen-free days vs placebo. These results do not support the hypotheses that pharmacological interventions that selectively block the angiotensin II type 1 receptor or increase angiotensin (1-7) improve outcomes for patients with severe COVID-19. Trial registration: ClinicalTrials.gov Identifier: NCT04924660.
The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19

Robert L Gottlieb,Meredith Clement,Paul Cook,Audra Deveikis,Kap Sum Foong,Philip Robinson,Jihad Slim,Cedric W Spak,Annemie Buelens,Katleen Callewaert,Sandra De Meyer,Wai Ling Mo,Inge Verbrugge,Liesbeth Van Wesenbeeck,Yanli Zhuang,Jason W Chien,Magda Opsomer,Erika Van Landuyt

DOI: https://doi.org/10.1016/j.jinf.2024.106241

Abstract:Background: Upregulation of IL-6 has been associated with worse prognosis in COVID-19 patients. Impact on IL-6 signalling has mostly been limited to clinical outcomes in IL-6 receptor antagonist trials. Methods: We performed a phase 2, randomised, double-blind, placebo-controlled trial (NCT04380961) of US-based hospitalised adults (<85 years) with laboratory-confirmed SARS-CoV-2 infection and severe (low levels of supplemental oxygen) or critical disease (high levels of oxygen supplementation). Patients received sirukumab 5 mg/kg or placebo single dose IV on Day 1 plus standard of care. The primary endpoint was time to sustained clinical improvement up to Day 28 based on an ordinal scale. Secondary endpoints included clinical improvement, all-cause mortality, and safety. Following an interim analysis, the protocol was amended to only recruit patients with critical COVID-19. Findings: From May 2020 to March 2021, 209 patients were randomised; 112 had critical disease (72 sirukumab, 40 placebo) at baseline. Median time to sustained clinical improvement in critical patients was 17 and 23 days in the sirukumab and placebo groups (HR, 1∙1; 95% CI, 0∙66-1∙88; p > 0∙05). At Day 28, 59∙4% versus 55∙0% of patients achieved clinical improvement with sirukumab versus placebo and rates of all-cause mortality were 24∙6% versus 30∙0%, respectively. Rates of grade ≥3 adverse events were comparable between the sirukumab and placebo groups (25∙9% vs 32∙9%; all patients). Interpretation: In critical COVID-19 patients who received sirukumab, there was no statistically significant difference in time to sustained clinical improvement versus placebo despite objective sequestration of circulating IL-6, questioning IL-6 as a key therapeutic target in COVID-19.
Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial

Kara W Chew,Babafemi O Taiwo,Carlee Moser,Eric S Daar,David Alain Wohl,Justin Ritz,Arzhang Cyrus Javan,Jonathan Z Li,William Fischer,Alexander L Greninger,Christoph Bausch,Thomas Luke,Robert Call,Gene Neytman,Mark J Giganti,Courtney V Fletcher,Michael D Hughes,Joseph J Eron,Judith S Currier,Davey M Smith,Kara Chew,David (Davey) Smith,Eric Daar,David Wohl,Judith Currier,Joseph Eron,Arzhang Cyrus Javan,Michael Hughes,Carlee Moser,Mark Giganti,Justin Ritz,Lara Hosey,Jhoanna Roa,Nilam Patel,Kelly Colsh,Irene Rwakazina,Justine Beck,Scott Sieg,Jonathan Li,Courtney Fletcher,William Fischer,Teresa Evering,Rachel Bender Ignacio,Sandra Cardoso,Katya Corado,Prasanna Jagannathan,Nikolaus Jilg,Alan Perelson,Sandy Pillay,Cynthia Riviere,Upinder Singh,Babafemi Taiwo,Joan Gottesman,Matthew Newell,Susan Pedersen,Joan Dragavon,Cheryl Jennings,Brian Greenfelder,William Murtaugh,Jan Kosmyna,Morgan Gapara,Akbar Shahkolahi,For the ACTIV-2/A5401 Study Team

DOI: https://doi.org/10.1093/infdis/jiae369

2024-07-20

The Journal of Infectious Diseases

Abstract:Background To address the need for novel COVID-19 therapies, we evaluated the fully-human polyclonal antibody product SAB-185 in a phase 3 clinical trial. Methods Non-hospitalized high-risk adults within 7 days of COVID-19 symptom onset were randomized 1:1 to open-label SAB-185 3,840 units/kg or casirivimab/imdevimab 1200 mg. Non-inferiority comparison was undertaken for the pre-Omicron population (casirivimab/imdevimab expected to be fully active) and superiority comparison for the Omicron population (casirivimab/imdevimab not expected to be active). Primary outcomes were the composite of all-cause hospitalizations/deaths and grade ≥3 treatment-emergent adverse events (TEAEs) through day 28. Secondary outcomes included time to sustained symptom improvement and resolution. Results Enrollment was terminated early due to low hospitalization/death rates upon Omicron emergence. 733 adults were randomized, 255 included in pre-Omicron and 392 in Omicron analysis populations. Hospitalizations/deaths occurred in 6 (5.0%) and 3 (2.2%) of pre-Omicron SAB-185 and casirivimab/imdevimab arms, respectively (absolute difference [95% CI] 2.7% [-2.3%, 8.6%]), inconclusive for non-inferiority; and 5 (2.5%) versus 3 (1.5%) (absolute difference 1.0% [-2.3%, 4.5%]) for Omicron. Risk ratios for grade ≥3 TEAEs were 0.94 [0.52, 1.71] (pre-Omicron) and 1.71 [0.96, 3.07] (Omicron). Time to symptom improvement and resolution were shorter for SAB-185, median 11 vs 14 (pre-Omicron) and 11 vs 13 days (Omicron) (symptom improvement), and 16 vs 24 days and 18 vs >25 days (symptom resolution), p<0.05 for symptom resolution for Omicron only. Conclusions SAB-185 had an acceptable safety profile with faster symptom resolution in the Omicron population. Additional studies are needed to characterize its efficacy for COVID-19.

immunology,infectious diseases,microbiology

Metal-enhanced intrinsic fluorescence of nucleic acids using platinum nanostructured substrates.

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid Collaborative

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Giants in Chest Medicine: Claude Lenfant, MD.

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial

A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial

Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial

Efficacy and Safety of Tocilizumab and Baricitinib among Patients Hospitalized for COVID-19: a Systematic Review and Meta-Analysis

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease

A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)

The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis

Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials

The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19

Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial